TransMedics Group, Inc. TMDX Liver Product — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about TransMedics Group, Inc.'s liver product — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TransMedics Group, Inc.'s liver product — revenue?
- TransMedics Group, Inc. (TMDX) reported liver product — revenue of $138.98M in Q1 2026.
- How has TransMedics Group, Inc.'s liver product — revenue changed year-over-year?
- TransMedics Group, Inc.'s liver product — revenue increased by 27.7% year-over-year, from $108.86M to $138.98M.
- What is the long-term trend for TransMedics Group, Inc.'s liver product — revenue?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s liver product — revenue has grown at a 293.8% compound annual growth rate (CAGR), from $1.92M to $460.53M.
- What does liver product — revenue mean?
- This metric represents the total gross sales generated from the sale of medical devices, disposables, and associated services specifically related to liver organ perfusion and preservation technology. It serves as a key indicator of the commercial adoption and market penetration of the company's organ care systems within the liver transplant clinical community. Growth in this revenue stream reflects the company's ability to displace traditional cold storage methods and expand its footprint in the end-stage liver disease treatment market.